

Blinded phase: ACR

Table 1: ACR Pedi response at 1 month

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=46	N=25	N=71
30	12 (12.5%)	7 (24.1%)	19 (15.2%)
50	7 (9.5%)	7 (25.9%)	14 (13.9%)
70	2 (4.3%)	5 (27.8%)	7 (10.8%)
90	2 (5.4%)	1 (10%)	3 (6.4%)
100	1 (6.3%)	0 (0%)	1 (5.3%)

Table 2: ACR Pedi response at 2 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=45	N=21	N=66
30	16 (16.7%)	8 (27.6%)	24 (19.2%)
50	10 (13.5%)	7 (25.9%)	17 (16.8%)
70	5 (10.6%)	3 (16.7%)	8 (12.3%)
90	3 (8.1%)	1 (10%)	4 (8.5%)
100	1 (6.3%)	1 (33.3%)	2 (10.5%)

Table 3: ACR Pedi response at 3 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=43	N=16	N=59
30	16 (16.7%)	6 (20.7%)	22 (17.6%)
50	13 (17.6%)	5 (18.5%)	18 (17.8%)
70	9 (19.1%)	3 (16.7%)	12 (18.5%)
90	7 (18.9%)	2 (20%)	9 (19.1%)
100	2 (12.5%)	1 (33.3%)	3 (15.8%)

Table 4: ACR Pedi response at 6 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=37	N=9	N=46
30	13 (13.5%)	3 (10.3%)	16 (12.8%)
50	11 (14.9%)	3 (11.1%)	14 (13.9%)
70	9 (19.1%)	3 (16.7%)	12 (18.5%)
90	6 (16.2%)	2 (20%)	8 (17%)
100	2 (12.5%)	1 (33.3%)	3 (15.8%)

Table 5: ACR Pedi response at 9 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=32	N=4	N=36
30	10 (10.4%)	1 (3.4%)	11 (8.8%)
50	9 (12.2%)	1 (3.7%)	10 (9.9%)
70	7 (14.9%)	1 (5.6%)	8 (12.3%)
90	7 (18.9%)	1 (10%)	8 (17%)
100	5 (31.3%)	0 (0%)	5 (26.3%)

Table 6: ACR Pedi response at 12 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=28	N=3	N=31
30	12 (12.5%)	2 (6.9%)	14 (11.2%)
50	10 (13.5%)	2 (7.4%)	12 (11.9%)
70	5 (10.6%)	1 (5.6%)	6 (9.2%)

90	5 (13.5%)	1 (10%)	6 (12.8%)
100	3 (18.8%)	0 (0%)	3 (15.8%)

Table 7: ACR Pedi response at 15 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=22	N=2	N=24
30	8 (8.3%)	1 (3.4%)	9 (7.2%)
50	6 (8.1%)	1 (3.7%)	7 (6.9%)
70	5 (10.6%)	1 (5.6%)	6 (9.2%)
90	4 (10.8%)	1 (10%)	5 (10.6%)
100	1 (6.3%)	0 (0%)	1 (5.3%)

Table 8: ACR Pedi response at 18 months

ACR Pedi Response	Adalimumab (n (%))	Placebo (n (%))	Total (n (%))
	N=19	N=2	N=21
30	9 (9.4%)	1 (3.4%)	10 (8%)
50	8 (10.8%)	1 (3.7%)	9 (8.9%)
70	5 (10.6%)	1 (5.6%)	6 (9.2%)
90	3 (8.1%)	1 (10%)	4 (8.5%)
100	1 (6.3%)	0 (0%)	1 (5.3%)